Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

AKBA Relative to the S&P 500

AKBA Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Akebia Therapeutics, Inc. (NASD:AKBA) seasonal charts above shows that a Buy Date of December 14 and a Sell Date of March 22 has resulted in a geometric average return of 11.74% above the benchmark rate of the S&P 500 Total Return Index over the past 11 years. This seasonal timeframe has shown positive results compared to the benchmark in 9 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 11 years by an average of 38.01% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vafseo. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

To download AKBA seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: AKBA